Peptide Initiative

Peptides · Peptide comparison

Pemvidutide vs Tirzepatide

Balanced dual GLP-1/glucagon receptor agonist with no dose titration required and breakthrough therapy designation for MASH.

The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.

  • Weight Management
  • Weight Management

At a glance

Quick comparison

Dose rangePemvidutide1.8–1.8 mgTirzepatide5–10 mg
FrequencyPemvidutideOnce dailyTirzepatideOnce weekly
AdministrationPemvidutideSubcutaneous injectionTirzepatideSubcutaneous injection
Cycle lengthPemvidutideOngoing/indefiniteTirzepatideOngoing/indefinite
Onset speedPemvidutideModerate (1-2 weeks)TirzepatideModerate (1-2 weeks)
Evidence levelPemvidutideModerate human trials (Phase 1-2)TirzepatideStrong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Weight Loss

Pemvidutide92%
Tirzepatide99%

Liver Health

Pemvidutide95%
TirzepatideNo recorded rating

Metabolic Health

Pemvidutide88%
TirzepatideNo recorded rating

Appetite Control

PemvidutideNo recorded rating
Tirzepatide97%

Blood Sugar Control

PemvidutideNo recorded rating
Tirzepatide96%

Technical data

Compound specifications

Pemvidutide

Molecular formula
C182H275N39O54
Molecular weight
3873.35 Da
Half-life
Approximately 110 hours (4.6 days)
Bioavailability
Subcutaneous bioavailability consistent with glycolipid-conjugated peptide therapeutics
CAS number
2538014-94-5

Tirzepatide

Molecular formula
C225H348N48O68
Molecular weight
4813.45 g/mol
Half-life
Approximately 5 days (120 hours)
Bioavailability
~80% (subcutaneous)
CAS number
2023788-19-2

Protocols

Dosing compared

Pemvidutide

Subcutaneous

  • 48 weeks1.2 mgOnce weekly · 48 weeksLowest dose studied; given at full strength from week 1 with no titration. Produced ~10% weight loss at 48 weeks in the MOMENTUM Phase 2 obesity trial [6] and is the lower MASH dose in the IMPACT Phase 2b trial [7].
  • 48 weeks1.8 mgOnce weekly · 48 weeksMid dose, started at full strength with no titration; ~11% weight loss at 48 weeks (MOMENTUM) [6] and the higher MASH dose in IMPACT [7].
  • 48 weeks2.4 mgOnce weekly · 48 weeksHighest dose; reached via a 4-week titration in MOMENTUM, where it produced 15.6% weight loss at 48 weeks [6].

Tirzepatide

Subcutaneous injection

  • First 4 weeks2.5 mgOnce weekly · First 4 weeksFDA label starting dose; non-therapeutic, used only to improve GI tolerability before escalating [5]. Inject in abdomen, thigh, or upper arm and rotate sites.
  • Increase by 2.5 mg after at least 4 weeks at each dose5-10 mgOnce weekly · Increase by 2.5 mg after at least 4 weeks at each dosePer FDA label, increase to 5 mg after 4 weeks; further increases in 2.5 mg steps no sooner than every 4 weeks as needed [5].
  • Ongoing maintenance12.5-15 mgOnce weekly · Ongoing maintenance15 mg is the maximum FDA-labeled dose [5]. SURMOUNT-1 used up to 15 mg weekly for obesity [1].

Applications

Best suited for

Pemvidutide

Adults seeking substantial weight loss without complex dose titration
Pemvidutide is particularly well-suited for individuals focused on adults seeking substantial weight loss without complex dose titration. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Individuals with concurrent MASH/NAFLD and obesity requiring dual-target therapy
Pemvidutide is particularly well-suited for individuals focused on individuals with concurrent mash/nafld and obesity requiring dual-target therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][3].
Patients with metabolic syndrome who need comprehensive risk factor improvement
Pemvidutide is particularly well-suited for individuals focused on patients with metabolic syndrome who need comprehensive risk factor improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those interested in investigational dual agonist therapies with strong early data
Pemvidutide is particularly well-suited for individuals focused on those interested in investigational dual agonist therapies with strong early data. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][3].

Tirzepatide

People Who Want Maximum Weight Loss Results
If you're serious about losing significant weight, tirzepatide delivers results that were previously only achievable through bariatric surgery. Clinical trials showed average weight loss exceeding 20% of body weight—that's 50+ pounds for someone starting at 250 pounds. No other medication comes close [1].
Those Who Haven't Succeeded with Semaglutide
Thanks to its dual GIP/GLP-1 mechanism, tirzepatide often works better for people who had limited results with GLP-1-only drugs like semaglutide. The added GIP activation provides extra metabolic benefits that can break through plateaus and deliver superior weight loss [2][9].
People with Type 2 Diabetes Needing Aggressive Control
Head-to-head trials proved tirzepatide beats semaglutide for blood sugar control. The average HbA1c reduction of over 2 percentage points means many people can dramatically reduce or eliminate other diabetes medications. It's a genuine game-changer for metabolic health [2].
Individuals Looking to Transform Their Relationship with Food
Tirzepatide doesn't just reduce hunger—it fundamentally changes how food appeals to you. Users describe feeling free from constant food thoughts, finding it easy to stop eating when satisfied, and losing interest in formerly irresistible treats. It's not willpower—it's biochemistry working for you [11].

Safety profile

Side effects

Pemvidutide

Common

  • Nausea
  • Diarrhea
  • Headache

Uncommon

  • Vomiting
  • Decreased Appetite

Serious

  • Acute Pancreatitis
  • Severe Gastrointestinal Disturbance

Tirzepatide

Common

  • Nausea
  • Diarrhea
  • Decreased Appetite
  • Vomiting

Uncommon

  • Gallbladder Problems
  • Hair Thinning (Telogen Effluvium)

Serious

  • Pancreatitis
  • Thyroid Tumors (Theoretical Risk)

Research status

Safety & evidence

Pemvidutide

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Pemvidutide (ALT-801, developed by Altimmune; a GLP-1/glucagon dual agonist) [3][5] completed Phase IIb obesity trials with favorable cardiovascular safety profile. Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30-40% of subjects, more prominent than GLP-1 monotherapy due to GCG receptor activation. Pancreatitis risk and elevated calcitonin levels require monitoring. No serious cardiac safety signals despite dual receptor activation; heart rate increases of 5-10 bpm observed.

Contraindications

  • Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
  • Known hypersensitivity to pemvidutide or formulation components
  • History of acute pancreatitis
  • Severe hepatic decompensation (Child-Pugh C cirrhosis)

Tirzepatide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Tirzepatide has been extensively studied in the SURPASS (diabetes) and SURMOUNT (obesity) trial programs, involving thousands of participants over multiple years. [1][2][3] The FDA approved it after thorough safety review. [5][6] While GI side effects are common (especially during dose increases), they're typically mild to moderate and improve over time. [5][6] Serious adverse events are rare. The SURPASS-CVOT trial is ongoing to evaluate long-term cardiovascular outcomes. [16]

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC) [6]
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [6]
  • History of serious allergic reaction to tirzepatide [6] or any GLP-1/GIP medication

Decision guide

Which is right for you?

Pemvidutide

Choose Pemvidutide if…

  • Adults seeking substantial weight loss without complex dose titration
  • Individuals with concurrent MASH/NAFLD and obesity requiring dual-target therapy
  • Patients with metabolic syndrome who need comprehensive risk factor improvement
  • Those interested in investigational dual agonist therapies with strong early data

Tirzepatide

Choose Tirzepatide if…

  • Maximum weight loss results
  • Long-term obesity management
  • Type 2 diabetes control
  • Metabolic health improvement